Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's episode: muscling into the obesity market; AbbVie’s schizophrenia failure; Bayer will not take risky bets; generally strong Q2 for Japanese majors; and AstraZeneca juggles China and growth questions.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

More from Podcasts

More from Scrip